Is Ozempic Safe? What Years of Semaglutide Data Say About Risks and Benefits

The pharmacist at a neighborhood counter recently told a customer, half joking, that she now answers one question more than any other: “is Ozempic safe?” She is not alone. Search interest has spiked again because the evidence keeps moving. In January 2025 US regulators added chronic kidney disease in people with type 2 diabetes to Ozempic’s approved uses, following a trial stopped early for benefit. Months later, European regulators concluded that a rare optic-nerve condition is a genuine, if very uncommon, side effect of semaglutide. Each announcement produced a new round of viral posts, some reassuring, some alarming.

As of September 2026, semaglutide has been studied in randomized trials enrolling more than 40,000 people and used by millions more in everyday practice. That is an unusually deep safety record for a medicine this young, and it allows a more honest conversation than the headlines offer.

What follows is a plain reading of that record: what the trials found, how strong each finding is, which risks are real but rare, and which claims simply do not hold up.

What changed recently: the dates behind the latest safety headlines

Three developments explain why the question feels urgent again. Each is dated, and each is tied to published evidence rather than rumor.

In November 2023 the SELECT trial, published in the New England Journal of Medicine and indexed on PubMed, reported that semaglutide reduced the combined rate of heart attack, stroke and cardiovascular death by 20 percent in 17,604 adults with obesity or overweight and existing heart disease but no diabetes. That finding led, in March 2024, to a US approval for the higher-dose weight-management version of semaglutide (sold as Wegovy) to reduce cardiovascular risk. The same molecule sits inside Ozempic.

In May 2024 the FLOW trial, which enrolled 3,533 people with type 2 diabetes and chronic kidney disease, reported a 24 percent reduction in major kidney events, including kidney failure and death from kidney or heart causes. US regulators approved Ozempic for this use in January 2025. A kidney benefit of that size in a diabetes medicine is rare, and it changed how clinicians weigh risks against rewards.

On the safety side, a 2024 observational study flagged a possible link between semaglutide and non-arteritic anterior ischemic optic neuropathy, or NAION, a sudden loss of blood flow to the optic nerve that can damage vision. In June 2025 the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect, affecting up to one in 10,000 users, and asked for it to appear in product information. Earlier, in 2023, US labeling added a warning about ileus, a slowing or blockage of the bowel.

One more shift matters for safety: in February 2025 US regulators declared the semaglutide shortage over. That ended the temporary allowance under which compounded copies had been widely made, and it pushed many people back toward prescribed, regulator-reviewed products. The sections below explain what all of this means for an individual deciding, with a clinician, whether this medicine fits.

Is Ozempic safe? The short, evidence-graded answer

Safety in medicine is never a yes or no. It is a balance of likely benefit, likely harm and the alternatives, judged for a particular person. On that scale, Ozempic sits in a favorable position for its approved uses.

The strongest evidence comes from randomized controlled trials, the type of study in which participants are assigned by chance to the medicine or a placebo so that differences can be credited to the drug. For semaglutide, these trials have run for one to five years, enrolled people in their fifties, sixties and seventies with multiple health conditions, and tracked every serious event. Across them, people taking semaglutide did not die more often, did not have more cancers overall, and had fewer heart and kidney events than those on placebo. That is grade-A evidence by any guideline standard.

The common harms are also well documented and mostly predictable: digestive upset in roughly one in three to one in two people early on, usually easing within weeks. The rare harms, pancreatitis, gallbladder disease, severe constipation, NAION and worsening of pre-existing diabetic eye disease, are real but infrequent, and most appear at rates of a few extra cases per thousand people treated, or less.

What the evidence cannot yet tell us is what happens after 20 or 30 years of continuous use, because no one has taken semaglutide that long. Rodent studies produced thyroid C-cell tumors, and the human relevance remains uncertain; this is the reason for the boxed warning in US labeling, described in detail later.

So the honest summary: for an adult with type 2 diabetes, especially one with heart or kidney disease, the documented benefits are substantial and the documented harms are mostly manageable. Whether that balance applies to you is a conversation for your prescribing clinician, who knows your history.

What is Ozempic, and how does semaglutide work in the body?

Ozempic is the brand name for a once-weekly injection of semaglutide, approved in the US in 2017 for adults with type 2 diabetes. Semaglutide belongs to a class called GLP-1 receptor agonists, medicines that mimic glucagon-like peptide-1, a hormone the gut releases after eating.

The natural hormone lasts only a couple of minutes in the bloodstream. Semaglutide is engineered to bind to a blood protein called albumin, which stretches its half-life to about a week. That single tweak is why it can be taken weekly rather than several times a day.

Once in circulation, it does four things that matter clinically. It prompts the pancreas to release insulin only when blood sugar is high, which is why it rarely causes low blood sugar on its own. It suppresses glucagon, a hormone that tells the liver to release stored sugar. It slows the emptying of the stomach, so meals feel filling for longer. And it acts on appetite centers in the brain, quieting what many patients describe as constant background hunger.

Those same mechanisms explain most of the side effects. A stomach that empties slowly can produce nausea, bloating and reflux. Rapid weight loss changes the composition of bile and can encourage gallstones. The appetite effect, welcome for many, can tip into eating too little if not monitored.

It helps to know that semaglutide comes in three approved forms: Ozempic for type 2 diabetes and related heart and kidney protection, Wegovy for weight management and cardiovascular risk reduction in people with obesity, and Rybelsus, a daily tablet for diabetes. The molecule is the same; the approved populations and doses differ. Much of the weight-loss data discussed online comes from the higher Wegovy dose rather than from Ozempic as labeled, a distinction that matters when reading any headline.

What the evidence actually says: grading the trials

Not all evidence weighs the same, so here is a tiered look at what supports each claim about semaglutide.

Randomized trials (strongest). SUSTAIN-6, published in 2016, followed 3,297 people with type 2 diabetes for about two years and found a 26 percent lower rate of major cardiovascular events with semaglutide. SELECT extended that finding to 17,604 people without diabetes over an average of 3.3 years, with a 20 percent relative reduction; in absolute terms, 6.5 percent of the semaglutide group had an event compared with 8.0 percent on placebo. FLOW showed a 24 percent reduction in major kidney events in 3,533 people with diabetes and chronic kidney disease. STEP 1, the landmark weight trial at the higher dose, recorded an average 14.9 percent loss of body weight over 68 weeks versus 2.4 percent with placebo. These are consistent, large and replicated results.

Observational data (moderate). Signals such as the NAION eye finding and possible links to gastroparesis come from database and cohort studies, which can identify associations but cannot fully separate the medicine’s effect from the health of the people who take it. People prescribed semaglutide tend to have diabetes and obesity, both of which independently raise eye and gut risks. Regulators treat these signals seriously, and in the NAION case concluded a causal link is plausible, while stressing the absolute risk is very small.

Expert opinion and mechanism (weakest). Claims about muscle loss, mood changes, dental problems or “Ozempic face” largely rest on small studies, case reports or biological reasoning. Some have been investigated and not confirmed: a 2024 review by US regulators found no evidence that GLP-1 medicines cause suicidal thoughts, and European regulators reached the same conclusion.

The pattern is reassuring. The benefits sit at the top of the evidence pyramid; most of the frightening claims sit near the bottom, and the genuinely serious rare harms are acknowledged in labeling and monitored by regulators.

Common Ozempic side effects: what the first months usually feel like

Ask a dozen people on semaglutide about the first six weeks and most describe the same thing: feeling full after half a plate, then a wave of queasiness if they eat the other half anyway.

In clinical trials, nausea affected roughly 15 to 20 percent of people on Ozempic at diabetes doses and up to 44 percent at the higher weight-management dose. Diarrhea, vomiting, constipation and abdominal pain followed in frequency. Most episodes were mild to moderate, peaked while the dose was being increased, and faded as the body adapted. Fewer than one in ten trial participants stopped the medicine because of digestive symptoms, though real-world discontinuation is higher.

Why does this happen? A stomach that empties slowly holds food longer, stretching its walls and sending nausea signals. Smaller meals, slower eating, and avoiding very fatty or greasy food tend to help, and clinicians often adjust the pace of dose increases for people who struggle; that pacing is their call, not a do-it-yourself project.

Other common effects include fatigue, headache, dizziness, burping with a sulfur taste, reflux and mild injection-site reactions such as redness or itching. Many people also notice a fall in appetite for alcohol, an effect now under formal study.

Low blood sugar deserves a specific note. On its own, semaglutide rarely pushes glucose dangerously low because it stimulates insulin only when sugar is elevated. The picture changes when it is combined with insulin or a sulfonylurea (an older class of diabetes tablets that forces insulin release regardless of glucose). In those combinations, trials recorded hypoglycemia in a meaningful minority, which is why clinicians typically reassess the other medicines when starting Ozempic.

Dehydration from vomiting or diarrhea is the quiet complication to respect. It can strain the kidneys, and acute kidney injury has been reported in people who became significantly dehydrated. Drinking fluids steadily and reporting persistent vomiting are two of the most useful things a patient can do.

Does Ozempic cause pancreatitis?

Pancreatitis, inflammation of the pancreas that causes severe, persistent upper-abdominal pain often radiating to the back, is the risk people most often ask about. The answer has two parts, and both matter.

First, the trials. Across the SUSTAIN program in diabetes and the STEP and SELECT programs in obesity, acute pancreatitis occurred in roughly 0.2 to 0.3 percent of participants per year, and the rates were not statistically higher with semaglutide than with placebo. A pooled analysis of GLP-1 trials in tens of thousands of people reached the same conclusion: no clear increase. That is good-quality evidence against a large effect.

Second, the pharmacovigilance record. Spontaneous reports of pancreatitis in people using GLP-1 medicines have accumulated since the first drug in the class was approved in 2005, and some observational studies have found a modest association. Because trials exclude people with a history of pancreatitis, and because reports cannot establish cause, regulators have kept a warning in the labeling rather than removing it. The warning states that pancreatitis has been reported, that the medicine should be stopped if it is suspected, and that it has not been studied in people with prior pancreatitis.

How should a reader weigh this? Type 2 diabetes and obesity themselves roughly double the background risk of pancreatitis, which complicates every observational comparison. The randomized data, which handle that problem by design, do not show a signal. The prudent interpretation used by most guideline bodies is that semaglutide is unlikely to cause pancreatitis in most people, but that a rare effect in susceptible individuals cannot be excluded, so the symptom should never be ignored.

Gallstones are a related and better-documented issue. Rapid weight loss of any kind increases gallstone formation, and trials recorded gallbladder disease in about 1 to 3 percent of semaglutide users versus roughly 1 percent on placebo. Gallstones can themselves trigger pancreatitis, which may explain part of the observational signal.

Thyroid tumors, gallbladder and eyes: the rarer risks explained

Ozempic carries a boxed warning, the strongest caution in US labeling, about thyroid C-cell tumors. It helps to understand exactly where that warning comes from.

In long-term rodent studies, semaglutide and other GLP-1 medicines caused tumors of the thyroid’s C cells, which produce the hormone calcitonin. Rodents have many more C cells with GLP-1 receptors than humans do, and their thyroid responds to the drug class in a way human thyroid tissue does not appear to share. Whether the finding translates to people is unknown. Human trials spanning more than 15 years of GLP-1 use have not shown an increase in medullary thyroid carcinoma, the cancer that arises from C cells, though this cancer is so rare (about one case per 500,000 people per year) that trials cannot fully rule out a small effect.

Because of that uncertainty, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or of multiple endocrine neoplasia type 2, an inherited syndrome that predisposes to it. For everyone else, the labeling asks clinicians to counsel patients about possible symptoms, such as a lump in the neck, trouble swallowing or persistent hoarseness, and to evaluate them if they appear.

Eye risks come in two forms. People with existing diabetic retinopathy, damage to the retina’s small blood vessels, had more retinopathy complications in SUSTAIN-6 (3.0 percent versus 1.8 percent on placebo). The leading explanation is that a rapid drop in blood sugar temporarily worsens fragile vessels, a phenomenon also seen with intensive insulin therapy. Regular eye checks are standard for anyone with diabetes starting treatment.

NAION is the newer concern. It is very rare, and the absolute number of extra cases is tiny, but sudden painless loss of vision in one eye is a medical emergency whatever the cause. Gallbladder disease, discussed above, rounds out the list of uncommon but recognized harms.

Ozempic side effects long term: what years of follow-up show

Semaglutide has now been followed in randomized settings for up to about five years, and the GLP-1 class for nearly two decades. The table below gathers the key outcome trials so the pattern is visible at a glance.

Trial (year published)	Who was studied	Follow-up	Main benefit found	Main safety observations
SUSTAIN-6 (2016)	3,297 adults with type 2 diabetes and high cardiovascular risk	About 2 years	26% fewer major cardiovascular events	More retinopathy complications in people with existing eye disease; more digestive side effects
STEP 1 (2021)	1,961 adults with obesity, no diabetes (higher dose)	68 weeks	Average 14.9% body-weight loss vs 2.4% placebo	Nausea, diarrhea, constipation common; gallbladder events slightly higher
SELECT (2023)	17,604 adults with obesity and heart disease, no diabetes	Average 3.3 years	20% fewer heart attacks, strokes and cardiovascular deaths	No excess pancreatitis or cancer; more discontinuation for digestive symptoms
FLOW (2024)	3,533 adults with type 2 diabetes and chronic kidney disease	Median 3.4 years	24% fewer major kidney events; lower all-cause death	Fewer serious adverse events overall than placebo

Two long-term themes stand out. One is that lean tissue, including muscle, accounts for an estimated 25 to 40 percent of total weight lost, a proportion similar to diet-induced weight loss. For older adults this is not trivial, and resistance exercise plus adequate protein are standard advice. The other is weight regain: in a STEP 1 extension, participants regained about two-thirds of lost weight within a year of stopping, and blood pressure and cholesterol improvements faded too. Obesity behaves like other chronic conditions in this respect; the medicine works while it is taken.

Bone density, mental health and dental effects have been raised as long-term questions. Current evidence does not show a harmful effect on any of them, but the data are thinner than for heart and kidney outcomes, and research continues.

Is Ozempic safe for weight loss when you don't have diabetes?

This is where the conversation gets tangled, because Ozempic as a product is approved for type 2 diabetes and its heart and kidney complications, not for weight management in people without diabetes. The weight-management approval belongs to Wegovy, which contains the same molecule at a higher maintenance dose and was tested in the STEP and SELECT trials.

Prescribing Ozempic to someone without diabetes purely for weight loss is therefore off-label, a term meaning use outside the conditions a regulator has formally approved. Off-label prescribing is legal and common in medicine, and in this case the supporting evidence is unusually strong because the identical drug has been studied in exactly that population. But the trials used Wegovy’s dosing, so the safety and efficacy numbers do not transfer precisely to Ozempic as labeled.

What does the evidence say about safety for people without diabetes? SELECT is the best answer: more than 17,000 participants with obesity and heart disease but no diabetes, followed for over three years, with fewer cardiovascular events and no increase in deaths, cancers or pancreatitis. Side effects mirrored the diabetes trials. In that sense, the molecule’s safety profile looks similar whether or not a person has diabetes.

Where caution is warranted is in people who do not meet the trial criteria at all: those with a body mass index in the healthy range seeking cosmetic weight loss, teenagers using adult products, or anyone with a history of an eating disorder. Rapid weight loss in people who do not carry excess weight brings risks, including loss of muscle, gallstones and nutritional deficiency, without the compensating health benefits the trials measured. No trial has shown benefit in that group.

The decision about whether an off-label prescription is appropriate, and which semaglutide product fits, belongs to the treating clinician, who can weigh medical need, alternatives and the individual’s history against the evidence.

Who should not take Ozempic?

Labeling and guidelines identify several groups for whom Ozempic is either contraindicated, meaning it should not be used, or requires particular caution.

Contraindicated outright are people with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia type 2, and anyone who has had a serious allergic reaction to semaglutide or any ingredient in the injection. Allergic reactions, including anaphylaxis and angioedema (deep swelling of the face, lips or throat), have been reported with GLP-1 medicines and are a reason to stop and seek urgent care.

Caution, rather than prohibition, applies to a longer list:

• People with a history of pancreatitis, because the medicine has not been studied in them and the labeling flags the uncertainty.
• People with diabetic retinopathy, who need eye monitoring as blood sugar improves.
• Anyone with severe gastrointestinal disease, including gastroparesis (delayed stomach emptying from nerve damage), since the drug slows the stomach further.
• People with type 1 diabetes, for whom semaglutide is not approved and does not replace insulin.
• Those taking insulin or sulfonylureas, who may need those medicines reviewed to avoid hypoglycemia.
• People with a history of suicidal thoughts or significant depression, where labeling advises monitoring even though regulators found no causal link.

Pregnancy and breastfeeding deserve their own note. Animal studies showed fetal harm, and semaglutide is not recommended during pregnancy. Because it stays in the body for weeks, labeling advises stopping it with a lead time before trying to conceive; the exact interval is specified by the prescriber. Evidence in breastfeeding is lacking.

Finally, anyone scheduled for surgery or a procedure under sedation should tell the anesthesia team they take a GLP-1 medicine. Slower stomach emptying raises the risk of regurgitation during anesthesia, and anesthesiology societies have issued guidance on when to pause the medicine. That timing is a clinical decision made for each patient.

Benefits beyond blood sugar: heart and kidney data

Safety is only half of any risk-benefit judgment. The other half is what the medicine delivers, and here the semaglutide story is unusually strong for a diabetes drug.

Start with glucose. In the SUSTAIN trials, Ozempic lowered HbA1c, the three-month average of blood sugar, by roughly 1.5 to 1.8 percentage points, more than most competing injectables and tablets. Average weight loss in those diabetes trials was about 4 to 6 kilograms, or roughly 9 to 13 pounds, over 30 to 56 weeks.

The heart findings matter more for longevity. Heart disease is the leading cause of death in people with type 2 diabetes, and SUSTAIN-6 showed fewer strokes in particular. SELECT then demonstrated that the protection extends to people without diabetes, and intriguingly the benefit began appearing within months, before most weight had been lost, suggesting mechanisms beyond weight alone: lower inflammation, lower blood pressure, and improved cholesterol are all candidates.

The kidney results from FLOW may prove the most consequential. The trial was stopped early because the benefit was clear: a 24 percent reduction in a composite of kidney failure, a sustained 50 percent fall in kidney function, and death from kidney or cardiovascular causes. All-cause mortality was 20 percent lower. For a condition that otherwise marches steadily toward dialysis, those are meaningful numbers.

Emerging data point elsewhere, too. Trials in heart failure with preserved ejection fraction, a form in which the heart pumps normally but fills stiffly, showed better symptoms and exercise capacity. A phase 3 trial in a liver condition called MASH (metabolic dysfunction-associated steatohepatitis) showed resolution of liver inflammation in a higher proportion of participants, and in 2025 US regulators granted an approval for the higher-dose product in that setting. Studies of sleep apnea, alcohol use and knee osteoarthritis pain are ongoing or recently reported.

None of this makes semaglutide a universal remedy. It does mean that for people with diabetes, obesity and cardiovascular or kidney disease, the benefits on the table are measured in heart attacks and dialysis sessions prevented, not in pounds alone.

Common myths about Ozempic, corrected

Viral claims travel faster than trial results. Here are the ones clinicians hear most, with what the evidence says.

“Ozempic causes thyroid cancer.” Rodents developed C-cell tumors; humans have not shown an increase across trials and more than 15 years of class use. The boxed warning exists because the question cannot be fully closed, not because a human link has been found.

“Ozempic paralyzes your stomach permanently.” Semaglutide slows stomach emptying by design, and in rare cases this becomes severe. Labeling now mentions ileus and gastroparesis. Reports describe symptoms resolving after stopping in most cases, and permanent damage has not been established.

“It makes you suicidal.” Reviews by US regulators in January 2024 and European regulators in April 2024 found no evidence that GLP-1 medicines cause suicidal thoughts or actions. Monitoring is still advised for people with a mental health history.

“Ozempic face is a side effect of the drug.” Facial volume loss follows any rapid, substantial weight loss, whether from medicine, surgery or diet. It is a consequence of fat loss, not a drug toxicity.

“It melts fat while you eat whatever you want.” Trials paired the medicine with lifestyle counseling, and participants ate less because they were less hungry. Weight loss reflects reduced intake, and roughly a quarter or more of lost weight is lean tissue unless protein and exercise are maintained.

“Once you stop, you’ll be heavier than when you started.” Most people regain a large share of lost weight after stopping, but trial extensions show they remained, on average, below their starting weight a year later. Regain is real; rebound overshoot is not what the data show.

“It’s just a vanity drug.” The heart and kidney outcome trials involve some of the sickest patients in diabetes care and show fewer deaths. Vanity is not what regulators approved it for.

Compounded and online semaglutide: what the regulatory status actually is

A meaningful part of the safety question has nothing to do with the molecule and everything to do with where it came from.

During the US semaglutide shortage, which regulators declared between 2022 and February 2025, pharmacy compounders were permitted to prepare copies of the medicine. Compounding is the preparation of a medicine for an individual patient when an approved product is unavailable or unsuitable. Compounded drugs are not reviewed by regulators for safety, effectiveness or quality before they are sold, and they carry none of the approved labeling that lists warnings and contraindications.

Once the shortage ended, that allowance lapsed, and compounded versions of semaglutide are no longer broadly permitted except in narrow circumstances for specific patients. Products sold online as “research-grade” semaglutide, semaglutide salts, or peptide vials for “research purposes only” fall outside any approved framework. They are not approved medicines, they are not intended for human use, and they are not for sale or self-use. Regulators have warned about vials containing the wrong strength, the wrong substance or contaminants, and poison centers in the US reported a sharp rise in calls involving semaglutide dosing errors in 2023, many linked to unapproved products supplied without proper labeling.

Why does this matter for a safety discussion? Every reassuring number in this article comes from trials of the approved, manufactured product, given under medical supervision, with a known strength in a pen designed to deliver it. None of that evidence applies to a vial of unknown origin drawn up with a syringe at home.

The practical upshot is simple. If a product is prescribed by a licensed clinician and dispensed by a licensed pharmacy as an approved medicine, the safety record described here is relevant. If it is not, no one can tell you whether it is safe, because no one has checked.

When to see a doctor: red flags on Ozempic

Most side effects of semaglutide are uncomfortable rather than dangerous and ease with time. A small number are not, and recognizing them early makes a real difference. Contact your prescribing clinician promptly, or seek emergency care, if any of the following occur.

• Severe, persistent abdominal pain, especially pain that radiates to the back, with or without vomiting. This is the classic picture of pancreatitis and needs same-day assessment.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools. These suggest gallstones or a blocked bile duct.
• Vomiting that will not stop, inability to keep fluids down, dizziness on standing, or very little urine. Dehydration can injure the kidneys quickly.
• Severe constipation with bloating and no passage of gas or stool, which may signal ileus or bowel obstruction.
• Sudden, painless loss of vision in one eye, or a new dark patch in your field of view. Treat this as an emergency; it may be NAION or a retinal problem.
• Any change in vision in a person with known diabetic retinopathy.
• A lump or swelling in the neck, hoarseness that does not resolve, or difficulty swallowing or breathing.
• Signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, hives, or trouble breathing.
• Symptoms of low blood sugar such as shakiness, sweating, confusion or a racing heart, particularly if you also take insulin or a sulfonylurea.
• New or worsening low mood, or any thoughts of harming yourself.

Routine check-ins matter as much as emergencies. Clinicians typically review blood sugar, kidney function, weight trajectory and eye health at intervals, and will want to know about pregnancy plans, upcoming surgery, or new medicines. Never stop, skip or adjust Ozempic on your own in response to a side effect or a headline; call the prescriber, describe what is happening, and let them decide the next step. Every judgment about continuing, pausing or changing this medicine belongs with the clinician who knows your full history.

Frequently asked questions

Who should not take Ozempic?

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take Ozempic, nor should anyone who has had a serious allergic reaction to semaglutide. It is not approved for type 1 diabetes or for use in pregnancy. Those with prior pancreatitis, diabetic retinopathy, severe gastrointestinal disease or who take insulin need an individual risk discussion with their prescriber before starting.

Can Ozempic cause pancreatitis?

Pancreatitis has been reported in people taking Ozempic, but large randomized trials did not find it more common than with placebo, at roughly 0.2 to 0.3 percent per year in both groups. Because diabetes and obesity independently raise pancreatitis risk, a rare drug effect cannot be fully excluded, so labeling advises stopping the medicine and seeking care if severe persistent abdominal pain develops.

How long does it take to lose 20 pounds on Ozempic?

There is no reliable timeline, and no outcome can be promised. In diabetes trials of Ozempic, average loss was about 9 to 13 pounds over roughly 30 to 56 weeks. At the higher weight-management dose studied in STEP 1, the average was 14.9 percent of body weight over 68 weeks, about 30 pounds for a 200-pound person. Individual results vary widely with diet, activity and genetics.

Where do you inject Ozempic?

Ozempic is given once weekly as a subcutaneous injection, meaning into the fatty layer just under the skin. The approved sites listed in labeling are the abdomen, thigh or upper arm, rotating locations to protect the skin. Your prescribing team or pharmacist demonstrates the technique with the pen when treatment starts, and the patient leaflet included with the medicine repeats the instructions.

What are the long-term side effects of Ozempic?

Over follow-up of up to about five years, the recognized long-term concerns are gallbladder disease, loss of lean muscle alongside fat, worsening of pre-existing diabetic eye disease, and very rare NAION. No increase in cancer, pancreatitis or death has appeared in trials. Effects beyond a decade are unknown because no one has used the medicine that long, which is why regulators continue to monitor it.

Is Ozempic safe for weight loss without diabetes?

The semaglutide molecule has been tested for over three years in more than 17,000 people with obesity but no diabetes, with fewer heart events and no excess deaths or cancers. However, Ozempic itself is approved for type 2 diabetes; the weight-management approval belongs to the higher-dose product Wegovy. Using Ozempic for weight loss without diabetes is off-label, and whether it is appropriate is a decision for the treating clinician.

Does Ozempic cause thyroid cancer?

Human trials and more than 15 years of GLP-1 medicine use have not shown an increase in thyroid cancer. The boxed warning stems from rodent studies in which semaglutide caused thyroid C-cell tumors; rodent thyroid tissue responds differently from human tissue. Because the question cannot be fully closed, people with a personal or family history of medullary thyroid carcinoma are advised not to take it.

What happens when you stop taking Ozempic?

Appetite typically returns within weeks, and most people regain a substantial share of lost weight; in one trial extension, about two-thirds was regained within a year, and blood pressure and cholesterol gains faded too. Blood sugar in people with diabetes usually rises again. Stopping should always be planned with the prescriber, who can adjust other medicines and lifestyle support rather than leaving the transition unmanaged.

Can Ozempic affect your eyes?

Yes, in two ways. People with existing diabetic retinopathy had more eye complications in one major trial, likely because rapid blood-sugar improvement temporarily stresses fragile vessels, so eye checks are standard. Separately, regulators concluded in 2025 that NAION, sudden optic-nerve damage causing painless vision loss, is a very rare side effect. Any sudden vision change needs same-day medical attention.

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide is prepared by pharmacies rather than manufactured as an approved product, and it is not reviewed for safety, strength or purity before use. The broad allowance for compounding ended when the US shortage was declared over in February 2025. Products sold online as research peptides are unapproved and not for human use. The trial safety record applies only to the approved medicine.

References

• Semaglutide Injection, MedlinePlus Drug Information
• GLP-1 Agonists, Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.